|Thursday, 01.11.2018||09:00 am - 12:15 pm|
|Raum||Kongresshaus, Sitzungsraum 7 (2nd floor)|
|Morning||Sitzungsraum 7 (2nd floor)|
|* Sponsored by International Virotherapy Center Limited, Dubai (United Arab Emirates)|
|09:00 - 09.45 am||
Development of Oncolytic Virotherapy
Despite significant progress in the treatment of certain forms of cancer, in general it remains a major cause of death. Most metastatic solid tumors remain incurable. Though modern therapies have added some years to the life of the average cancer patient, they have not reduced the patient's chances of dying from the disease. Therefore, new agents with novel mechanism of action and lacking cross-resistance to the currently available approaches are needed. Drugs that could be used either alone or in combination with other treatment modalities, that may be affordable, safe and acceptable for cancer patients.
|09:45 - 10:15 am||Break|
|10:15 - 11:00 am||
Immunotherapy with Oncolytic Virus ECHO-7 in clinical practice – case reports
Despite advances in cancer therapy over the last decade, including the introduction of targeted medicines and checkpoint inhibitors, cancer remains as one of the most pressing health care challenges. Therefore novel treatment strategies are at a demand.
|11:00 - 11:30 am||Break|
|11:30 am - 12:15 pm||
Oncolytic Virus in the multi-level treatment of advanced cancers
Advanced cancers issue a challenge as they often show a poor response to many well-established therapies, such as chemotherapy or radiotherapy. In addition, the risk for complications and side effects is significantly higher than in early stages of the disease. Therefore, the idea of a multi-level approach, combining different low or medium intensity procedures is reasonable but yet not entrenched in the guidelines. One of the most promising fields in treating advanced cancers is immune therapy. A rising number of targeted therapies, such as checkpoint inhibitors as well as cellular therapies like Dendritic cell vaccination are currently on hand. Synergistic to these approaches, the use of oncolytic virus offers an additional and non-invasive treatment option. With this lecture, we present a number of different late-stage cancers treated with a multi-level approach, comprising pharmacological, physical and immunologic procedures such as Insulin potentiated low dose chemotherapy, hyperthermia, photodynamic therapy, checkpoint inhibitors, Dendritic cells and oncolytic virus treatment. The results are promising and encourage to evolve the idea of a minimal invasive multi-level approach in the treatment of advanced cancers.